Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the unmet medical need and relevant endpoints in obstructive and non-obstructive Hypertrophic Cardiomyopathy (HCM)

Ticker(s): MYOK

Who's the expert?

Name: Dr Shaojun Wang - MD

Institution: The Permanente Medical Group (TPMG)

  • Invasive cardiologist a multi specialty group with 600 physicians. 
  • Group manages about 150-200 patients with Hypertrophic cardiomyopathy.
  • Familiar with the Mavacamten mechanism of action.

Interview Questions
Q1.

Please tell us about your clinical practice, background in treating Obstructive/Nonobstructive Hypertrophic/Dilated Cardiomyopathy, and research in the space. How many patients do you treat,what is the first line of therapy? What % of patients do not respond well to first line?

Added By: c_admin
Q2.

How much of a need for new treatments is still there? Which ones get prescribed often and under what specific circumstances?

Added By: c_admin
Q3.

Do you emphasize treating the underlying cause, or do you focus more on alleviating symptoms? How often does the enlarged myocardium regenerate to its normal size following medication?

Added By: c_admin
Q4.

What can you tell us about the recent P3 trial launch of mavacamten as an alternative to septal reduction therapy (SRT) ?

Added By: c_admin
Q5.

What are the risks/ benefits associated with surgical myectomy or alcohol septal ablation procedures?

Added By: c_admin
Q6.

What is Mavacamten’s mechanism of action leading to normalization of the number of myosin-actin cross-bridges?

Added By: c_admin
Q7.

How important is the allosteric control of beta cardiac myosin? Was it possible prior to the development of Mavacamten?

Added By: c_admin
Q8.

How likely would you be to switch your patients to Mavacamten if approved?

Added By: c_admin
Q9.

How important is the fact that mavacamten can be dosed to reduce left ventricular outflow tract (LVOT) gradient below the guideline-based definition for obstruction?

Added By: c_admin
Q10.

What are your views on using proBNP as an endpoint for noHCM? Are there other endpoints you think are more informative?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.